Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2019

Open Access 01-06-2019 | Breast Cancer | Preclinical study

Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up

Authors: Sherry X. Yang, Eric C. Polley

Published in: Breast Cancer Research and Treatment | Issue 2/2019

Login to get access

Abstract

Background

It remains unclear whether breast cancer subtypes are associated with clinical outcome in patients without any treatment including systemic and radiation therapy as an independent entity. Understanding the survival profiles among subtypes by treatment status could impact optimal selection of treatments.

Methods

Patients were diagnosed with invasive breast cancer from the community hospitals across four geographical regions of the United States. Expression of hormone receptor (HR) and HER2 in tumor specimens from 1169 patients was centrally determined by immunohistochemistry and fluorescence in situ; breast cancer was classified into HR+/HER2−, HR+/HER2+, triple-negative, and HER2+ subtypes. Overall survival (OS) at a median follow-up of about 15 years among subtypes in untreated patients and those with systemic treatments and radiotherapy was analyzed by Kaplan–Meier method and multivariable analysis adjusting for age, tumor size and grade, number of positive nodes, stage and breast cancer subtypes.

Results

Without treatment, breast cancer subtypes were not associated with OS (P = 0.983) and remained insignificant for prognosis by multivariable analysis after adjusting for confounders. This contrasted with a significant survival difference across the subtypes in patients with conventional therapies (P < 0.0001). Compared with HR+/HER2− subtype, triple-negative subtype (HR 1.5, 95% CI 1.11–2.04; P = 0.009) and HER2+ subtype (HR 2.18, 95% CI 1.48–3.28; P = 0.0001) were significantly associated with worse survival by multivariable analyses.

Conclusion

Breast cancer subtypes are not associated with survival in untreated patient population and, in contrast, significantly associated with prognosis in patients with conventional therapy. The data provide evidence of treatment-associated differential outcomes among breast cancer subtypes.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Early Breast Cancer Trialists’ Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444CrossRef
4.
Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P et al (2017) 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377:1836–1846CrossRefPubMedPubMedCentral
5.
McGuire WL (1978) Hormone receptors: their role in predicting prognosis and response to endocrine therapy. Semin Oncol 5:428–433PubMed
6.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712CrossRefPubMed
7.
AJCC Cancer Staging Manual, 8 ed. (2017). Springer, New York
8.
Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A et al (2016) Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw 14:324–354CrossRef
9.
Rugo HS, Rumble RB, Burstein HJ (2016) Endocrine therapy for hormone receptor positive metastatic breast cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract 12:583–587CrossRef
10.
Yang SX, Davidson NE (2019) Hormone receptors and endocrine therapy in breast cancer. In: Yang SX, Dancey J (eds) Handbook of therapeutic biomarkers in cancer
11.
Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH et al (2010) Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. J Clin Oncol 28:2974–2981CrossRefPubMedPubMedCentral
12.
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed
13.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–502CrossRefPubMed
14.
Brenton JD, Carey LA, Ahmed AA, Caldas C (2005) Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23:7350–7360CrossRefPubMed
15.
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedPubMedCentral
16.
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T et al (2012) A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 18:4465–4472CrossRefPubMedPubMedCentral
17.
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral
18.
Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL et al (2015) Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33:1340–1347CrossRefPubMedPubMedCentral
19.
Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA et al (2013) Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 140:463–473CrossRefPubMedPubMedCentral
20.
van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009CrossRefPubMed
21.
van ‘t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530–536CrossRef
22.
Glass AG, Donis-Keller H, Mies C, Russo J, Zehnbauer B, Taube S et al (2001) The Cooperative Breast Cancer Tissue Resource: archival tissue for the investigation of tumor markers. Clin Cancer Res 7:1843–1849PubMed
23.
Yang SX, Polley EC, Nguyen D (2017) Association of gammaH2AX at diagnosis with chemotherapy outcome in patients with breast cancer. Theranostics 7:945–951CrossRefPubMedPubMedCentral
24.
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795CrossRefPubMedPubMedCentral
25.
Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122CrossRefPubMed
26.
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM et al (2006) REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat 100:229–235CrossRefPubMed
27.
Prat A, Pineda E, Adamo B, Galvan P, Fernandez A, Gaba L et al (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–S35CrossRefPubMed
28.
Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365:671–679CrossRefPubMed
29.
Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al (2007) Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 25:1239–1246CrossRefPubMed
30.
Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167CrossRefPubMedPubMedCentral
31.
32.
33.
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T et al (2010) A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 16:5222–5232CrossRefPubMedPubMedCentral
34.
Early Breast Cancer Trialists’ Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D et al (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771–784CrossRef
35.
Early Breast Cancer Trialists’ Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378:1707–1716CrossRef
36.
Sjostrom M, Lundstedt D, Hartman L, Holmberg E, Killander F, Kovacs A et al (2017) Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the swedish breast cancer group 91 radiotherapy randomized clinical trial. J Clin Oncol 35:3222–3229CrossRefPubMed
37.
Pan XB, Chen RJ, Huang ST, Jiang YM, Zhu XD (2017) Systematic review and meta-analysis of the efficacy of breast conservation therapy followed by radiotherapy in four breast cancer subtypes. Oncotarget 8:57414–57420PubMedPubMedCentral
38.
Colleoni M, Sun Z, Price KN, Karlsson P, Forbes JF, Thurlimann B et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol 34:927–935CrossRefPubMedPubMedCentral
39.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734CrossRefPubMed
40.
Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379:111–121CrossRefPubMedPubMedCentral
41.
Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783–2790CrossRefPubMed
42.
Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL et al (2008) Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 26:2373–2378CrossRefPubMed
43.
Langlands FE, Horgan K, Dodwell DD, Smith L (2013) Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol 86:20120601CrossRefPubMedPubMedCentral
44.
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13:2329–2334CrossRefPubMed
45.
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA et al (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 106
46.
Gruosso T, Mieulet V, Cardon M, Bourachot B, Kieffer Y, Devun F et al (2016) Chronic oxidative stress promotes H2AX protein degradation and enhances chemosensitivity in breast cancer patients. EMBO Mol Med 8:527–549CrossRefPubMedPubMedCentral
Metadata
Title
Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up
Authors
Sherry X. Yang
Eric C. Polley
Publication date
01-06-2019
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05142-x

Other articles of this Issue 2/2019

Breast Cancer Research and Treatment 2/2019 Go to the issue

Clinical trial

Loss of HER2 after HER2-targeted treatment

Preclinical study

SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma

Brief Report

Corneal features in trastuzumab emtansine treatment: not a rare occurrence

Brief Report

Validation of the breast cancer surveillance consortium model of breast cancer risk

Preclinical study

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Epidemiology

Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits